COMPLEMENT LYSIS MEDIATED BY ENGINEERED MULTIPLE-DOMAIN FORMS OF THE THERAPEUTIC ANTIBODY CAMPATH-1H

COMPLEMENT LYSIS MEDIATED BY ENGINEERED MULTIPLE-DOMAIN FORMS OF THE THERAPEUTIC ANTIBODY CAMPATH-1H

Opis bibliograficzny
Główni autorzy:	Greenwood, J, Gorman, S, Routledge, E, Lloyd, I, Waldmann, H
Format:	Journal article
Wydane:	1994

Podobne zapisy

Engineering multiple-domain forms of the therapeutic antibody CAMPATH-1H: effects on complement lysis.
od: Greenwood, J, i wsp.
Wydane: (1994)

Efficient complement-mediated lysis of cells containing the CAMPATH-1 (CDw52) antigen.
od: Xia, M, i wsp.
Wydane: (1993)

Importance of antigen specificity for complement-mediated lysis by monoclonal antibodies.
od: Bindon, C, i wsp.
Wydane: (1988)

Therapeutic potential of monoclonal antibodies to the leukocyte-common antigen. Synergy and interference in complement-mediated lysis.
od: Bindon, C, i wsp.
Wydane: (1985)

Structure of the CAMPATH-1 antigen, a glycosylphosphatidylinositol-anchored glycoprotein which is an exceptionally good target for complement lysis.
od: Xia, M, i wsp.
Wydane: (1993)

A humanized monovalent CD3 antibody which can activate homologous complement.
od: Routledge, E, i wsp.
Wydane: (1991)

Reshaping a therapeutic CD4 antibody.
od: Gorman, S, i wsp.
Wydane: (1991)

A personal history of the CAMPATH-1H antibody.
od: Waldmann, H
Wydane: (2002)

Synergistic complement lysis by monoclonal antibodies to the human leukocyte common antigen requires both the classical and alternative pathways.
od: Bindon, C, i wsp.
Wydane: (1987)

Pilot study of CAMPATH-1, a rat monoclonal antibody that fixes human complement, as an immunosuppressant in organ transplantation.
od: Hale, G, i wsp.
Wydane: (1986)

Specificity of monoclonal antibody Campath-1.
od: Hale, G, i wsp.
Wydane: (1988)

1.9 A structure of the therapeutic antibody CAMPATH-1H fab in complex with a synthetic peptide antigen.
od: James, L, i wsp.
Wydane: (1999)

CAMPATH-1 monoclonal antibodies in bone marrow transplantation.
od: Hale, G, i wsp.
Wydane: (1994)

Prevention of immune-mediated corneal graft destruction with the anti-lymphocyte monoclonal antibody, CAMPATH-1H.
od: Newman, D, i wsp.
Wydane: (1995)

Availability of Campath-1 antibodies for bone marrow transplantation.
od: Hale, G, i wsp.
Wydane: (1995)

The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody.
od: Routledge, E, i wsp.
Wydane: (1995)

CAMPATH-IH in multiple sclerosis.
od: Moreau, T, i wsp.
Wydane: (1996)

TREATMENT OF RHEUMATOID-ARTHRITIS WITH HUMANIZED ANTILYMPHOCYTE ANTIBODY CAMPATH-1H
od: Watts, R, i wsp.
Wydane: (1992)

Monoclonal antibody therapy of diffuse cutaneous scleroderma with CAMPATH-1H.
od: Isaacs, J, i wsp.
Wydane: (1996)

CAMPATH-1 antibodies in stem-cell transplantation.
od: Hale, G, i wsp.
Wydane: (2001)

EFFECTS OF MONOCLONAL-ANTIBODIES OF THE CAMPATH SERIES INVIVO - REQUIREMENTS FOR EFFECTIVE ANTIBODY THERAPY
od: Dyer, M, i wsp.
Wydane: (1988)

ISOTYPE VARIANTS OF CAMPATH-1 ANTIBODY - REQUIREMENTS FOR EFFECTIVE ANTIBODY ACTION INVIVO
od: Dyer, M, i wsp.
Wydane: (1989)

Crystal structures of a rat anti-CD52 (CAMPATH-1) therapeutic antibody Fab fragment and its humanized counterpart.
od: Cheetham, G, i wsp.
Wydane: (1998)

Monoclonal antibody therapy of chronic intraocular inflammation using Campath-1H.
od: Isaacs, J, i wsp.
Wydane: (1995)

Effects of CAMPATH-1 antibodies in vivo in patients with lymphoid malignancies: influence of antibody isotype.
od: Dyer, M, i wsp.
Wydane: (1989)

Rat monoclonal antibodies for bone marrow transplantation--the CAMPATH series.
od: Waldmann, H, i wsp.
Wydane: (1985)

Recent results using CAMPATH-1 antibodies to control GVHD and graft rejection.
od: Hale, G, i wsp.
Wydane: (1996)

CAMPATH-1H in inflammatory arthritis.
od: Watts, R, i wsp.
Wydane: (1993)

Direct antibody rosette-forming reactions using monoclonal markers of lymphocyte subpopulations. Methodology and applications illustrated by investigations with rat pan-T antibodies of the CAMPATH series.
od: Wilson, AB, i wsp.
Wydane: (1986)

Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
od: Williams, R, i wsp.
Wydane: (2000)

RAT MONOCLONAL-ANTIBODIES FOR BONE-MARROW TRANSPLANTATION (BMT) - THE CAMPATH SERIES
od: Waldmann, H, i wsp.
Wydane: (1985)

Engraftment of marrow allografts treated with Campath-1 monoclonal antibodies.
od: Naparstek, E, i wsp.
Wydane: (1999)

CAMPATH-1 monoclonal antibody therapy in severe refractory autoimmune thrombocytopenic purpura.
od: Lim, S, i wsp.
Wydane: (1993)

The essential role of complement in antibody-mediated resistance to Salmonella
od: Rossi, O, i wsp.
Wydane: (2018)

Remission induction in non-Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H.
od: Hale, G, i wsp.
Wydane: (1988)

Reversal of allograft rejection using the monoclonal antibody, Campath-1G.
od: Friend, P, i wsp.
Wydane: (1991)

CAMPATH: from concept to clinic.
od: Waldmann, H, i wsp.
Wydane: (2005)

Therapy with monoclonal antibodies. An in vivo model for the assessment of therapeutic potential.
od: Isaacs, J, i wsp.
Wydane: (1992)

REMISSION INDUCTION IN PATIENTS WITH LYMPHOID MALIGNANCIES USING UNCONJUGATED CAMPATH-1 MONOCLONAL-ANTIBODIES
od: Dyer, M, i wsp.
Wydane: (1990)

Ex vivo T-cell depletion with the monoclonal antibody Campath-1 plus human complement effectively prevents acute graft-versus-host disease in allogeneic bone marrow transplantation.
od: Heit, W, i wsp.
Wydane: (1986)